LIQUIDIA CORPORATION Loss Contingency, Receivable, Proceeds
LIQUIDIA CORPORATION (LQDA) reported Loss Contingency, Receivable, Proceeds of $163.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:LossContingencyReceivableProceeds · last filed 2026-08-12
- LIQUIDIA CORPORATION loss contingency, receivable, proceeds for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- LIQUIDIA CORPORATION loss contingency, receivable, proceeds for the quarter ending 2026-03-31 was $163.00K, a 30.64% decline year-over-year.
- LIQUIDIA CORPORATION loss contingency, receivable, proceeds for the quarter ending 2025-12-31 was $100.00K, a 3.85% decline year-over-year.
- LIQUIDIA CORPORATION loss contingency, receivable, proceeds for the quarter ending 2025-09-30 was $314.00K, a 17.60% increase year-over-year.
- LIQUIDIA CORPORATION loss contingency, receivable, proceeds for fiscal 2025 was $1.08M, a 82.80% increase from fiscal 2024.
- LIQUIDIA CORPORATION loss contingency, receivable, proceeds for fiscal 2024 was $593.00K, a 424.78% increase from fiscal 2023.
- LIQUIDIA CORPORATION loss contingency, receivable, proceeds for fiscal 2023 was $113.00K, a 74.94% decline from fiscal 2022.
- LIQUIDIA CORPORATION loss contingency, receivable, proceeds for fiscal 2022 was $451.00K, a 90.96% decline from fiscal 2021.
| Period end | Loss Contingency, Receivable, Proceeds 3 month | Loss Contingency, Receivable, Proceeds 3 month as first filed | Loss Contingency, Receivable, Proceeds 6 month | Loss Contingency, Receivable, Proceeds 6 month as first filed | Loss Contingency, Receivable, Proceeds 9 month | Loss Contingency, Receivable, Proceeds 9 month as first filed | Loss Contingency, Receivable, Proceeds 12 month | Loss Contingency, Receivable, Proceeds 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $163.00K 10-Q · filed 2026-08-12 | $263.00K derived: sum of 3 quarters · filed 2026-08-12 | $577.00K derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | $163.00K 10-Q · filed 2026-05-11 | $263.00K derived: sum of 2 quarters · filed 2026-05-11 | $577.00K derived: sum of 3 quarters · filed 2026-05-11 | $1.01M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $414.00K derived: sum of 2 quarters · filed 2026-03-05 | $849.00K derived: sum of 3 quarters · filed 2026-08-12 | $1.08M 10-K · filed 2026-03-05 | ||||
| 2025-09-30 | $314.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $749.00K derived: sum of 2 quarters · filed 2026-08-12 | $984.00K 10-Q · filed 2025-11-03 | $1.09M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | $435.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $670.00K 10-Q · filed 2026-08-12 | $774.00K derived: sum of 3 quarters · filed 2026-08-12 | $1.04M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-03-31 | $235.00K 10-Q · filed 2026-05-11 | $339.00K derived: sum of 2 quarters · filed 2026-05-11 | $606.00K derived: sum of 3 quarters · filed 2026-05-11 | $825.00K derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | $104.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $371.00K derived: sum of 2 quarters · filed 2026-03-05 | $590.00K derived: sum of 3 quarters · filed 2026-03-05 | $593.00K 10-K · filed 2026-03-05 | ||||
| 2024-09-30 | $267.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $486.00K derived: sum of 2 quarters · filed 2025-11-03 | $489.00K 10-Q · filed 2025-11-03 | $493.00K derived: sum of 4 quarters · filed 2026-03-05 | ||||
| 2024-06-30 | $219.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $222.00K 10-Q · filed 2025-08-12 | $226.00K derived: sum of 3 quarters · filed 2026-03-05 | $234.00K derived: sum of 4 quarters · filed 2026-03-05 | ||||
| 2024-03-31 | $3.00K 10-Q · filed 2025-05-08 | $7.00K derived: sum of 2 quarters · filed 2026-03-05 | $15.00K derived: sum of 3 quarters · filed 2026-03-05 | $99.00K derived: sum of 4 quarters · filed 2026-03-05 | ||||
| 2023-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $12.00K derived: sum of 2 quarters · filed 2026-03-05 | $96.00K derived: sum of 3 quarters · filed 2026-03-05 | $113.00K 10-K · filed 2026-03-05 | ||||
| 2023-09-30 | $8.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $92.00K derived: sum of 2 quarters · filed 2024-11-13 | $109.00K 10-Q · filed 2024-11-13 | $139.00K derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $84.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $101.00K 10-Q · filed 2024-08-07 | $131.00K derived: sum of 3 quarters · filed 2024-08-07 | $183.00K derived: sum of 4 quarters · filed 2024-08-07 | ||||
| 2023-03-31 | $17.00K 10-Q · filed 2024-05-13 | $47.00K derived: sum of 2 quarters · filed 2024-05-13 | $99.00K derived: sum of 3 quarters · filed 2024-05-13 | $192.00K derived: sum of 4 quarters · filed 2024-05-13 | ||||
| 2022-12-31 | $30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $82.00K derived: sum of 2 quarters · filed 2024-03-13 | $175.00K derived: sum of 3 quarters · filed 2024-03-13 | $451.00K 10-K · filed 2024-03-13 | ||||
| 2022-09-30 | $52.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $145.00K derived: sum of 2 quarters · filed 2023-11-07 | $421.00K 10-Q · filed 2023-11-07 | $1.49M derived: sum of 4 quarters · filed 2023-11-07 | ||||
| 2022-06-30 | $93.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $369.00K 10-Q · filed 2023-08-10 | $1.44M derived: sum of 3 quarters · filed 2023-08-10 | $3.51M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $276.00K 10-Q · filed 2023-05-08 | $1.34M derived: sum of 2 quarters · filed 2023-05-08 | $3.42M derived: sum of 3 quarters · filed 2023-05-08 | $4.34M derived: sum of 4 quarters · filed 2023-05-08 | ||||
| 2021-12-31 | $1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $3.14M derived: sum of 2 quarters · filed 2023-03-20 | $4.06M derived: sum of 3 quarters · filed 2023-03-20 | $4.99M 10-K · filed 2023-03-20 | $4.99M 10-K · filed 2022-03-17 | |||
| 2021-09-30 | $2.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $2.99M derived: sum of 2 quarters · filed 2022-11-08 | $3.92M 10-Q · filed 2022-11-08 | $3.92M 10-Q · filed 2021-11-03 | $4.43M derived: sum of 4 quarters · filed 2022-11-08 | |||
| 2021-06-30 | $918.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $1.84M 10-Q · filed 2022-08-11 | $1.85M 10-Q · filed 2021-08-10 | $2.35M derived: sum of 3 quarters · filed 2022-08-11 | $2.35M derived: sum of 4 quarters · filed 2022-08-11 | |||
| 2021-03-31 | $927.00K 10-Q · filed 2022-05-12 | $926.91K 10-Q · filed 2021-05-13 | $1.43M derived: sum of 2 quarters · filed 2022-05-12 | $1.43M derived: sum of 3 quarters · filed 2022-05-12 | $1.43M derived: sum of 4 quarters · filed 2022-05-12 | |||
| 2020-12-31 | $507.85K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $507.85K derived: sum of 2 quarters · filed 2022-03-17 | $507.85K derived: sum of 3 quarters · filed 2022-03-17 | $507.85K 10-K · filed 2022-03-17 | ||||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $0.00 derived: sum of 2 quarters · filed 2021-11-03 | $0.00 10-Q · filed 2021-11-03 | |||||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $0.00 10-Q · filed 2021-08-10 | ||||||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-13 | |||||||
| 2019-12-31 | $0.00 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |